None
Home | All Articles | Entities | Email Newsletter | Comments | Login | Register
Categories: Bronchoscopy, Cardiology, Dentistry, Dermatology, Endoscopy, Glucose, Microscopy, Non-Medical, Ophthalmology, Acquisition, Funding, Jobs & Studentships, Partnership, Patents
Articles for category "Funding"
GlucoLight Corporation Raises Third Tranche Of ''c'' Round Financing
BETHLEHEM, Pa.--(BUSINESS WIRE)--GlucoLight Corporation, a development-stage company focused on non-invasive, continuous blood glucose monitoring, today announced the closing of the third
BETHLEHEM, Pa.--(BUSINESS WIRE)--GlucoLight Corporation, a development-stage company focused on non-invasive, continuous blood glucose monitoring, today announced the closing of the third
GlucoLight Corporation Raises Second Tranche of “c” Round Financing
Using Optical Coherence Tomography (OCT) based technology, GlucoLight has identified specific physiological targets within the dermis that closely correlate ...
Using Optical Coherence Tomography (OCT) based technology, GlucoLight has identified specific physiological targets within the dermis that closely correlate ...
GlucoLight Corporation Raises Second Tranche of ''c'' Round Financing
BETHLEHEM, Pa.--(BUSINESS WIRE)--GlucoLight Corporation, a development-stage company focused on non-invasive, continuous blood glucose monitoring, today announced the closing of the second
BETHLEHEM, Pa.--(BUSINESS WIRE)--GlucoLight Corporation, a development-stage company focused on non-invasive, continuous blood glucose monitoring, today announced the closing of the second
OCT market to top $800 million by 2012
Laser Focus World (Jan 29 2008)
Funding
Optical coherence tomography (OCT) is fast becoming the most successful optics technology to date in the field of disease diagnostics. Invented in the early 1990s at the Massachusetts Institute of Technology (Cambridge, MA) and first commercialized for medical applications by Carl Zeiss in 1996, OCT offers fast, high-resolution diagnostic images for a variety of clinical applications, plus the potential to supplant existing imaging modalities in some medical disciplines. According to ...
Optical Coherence Tomography Market To Top $800 Million By 2012
Photonics Online (Jan 14 2008)
Funding
According to "Optical Coherence Tomography -- Technology, Markets, and Applications: 2008-2012," a new market research report from the publishers of BioOptics World that quantifies this rapidly growing market for the first time, the global market for OCT systems is currently around $200 million and growing at an annual rate of 34%. This growth is expected to continue at this pace for the next several years, with revenues topping $800 million ...
Optical Coherence Tomography Market to Top $800 Million by 2012
Latest Press Releases (Jan 14 2008)
Funding
PR Newswire - NASHUA, N.H., Jan. 14 /PRNewswire/ -- Optical coherence tomography (OCT) is a unique imaging modality that is fast becoming the most successful optics technology to date in the field of disease diagnostics. Invented at MIT in the early 1990s and ...
Optical Coherence Tomography Market to Top $800 Million by 2012
earthtimes.org (Jan 14 2008)
Funding
14 -- Optical coherence tomography (OCT) is a unique imaging modality that is fast becoming the most successful optics technology to date in the field of ...
Imalux Awarded $2.3 Million Research Grant
home.businesswire.com (Nov 10 2007)
Funding
CLEVELAND--(BUSINESS WIRE)--Imalux Corporation (“Imalux”), a medical device company and developer of the Niris™ Imaging System based on Optical Coherence Tomography (“OCT”) technology, today announced the receipt of a Fast-Track research grant from the National Cancer Institute of the National Institutes of Health. The award of up to $2.3 million is to fund Imalux’s accelerated development of video rate Optical Coherence Tomography for early stage cance
Imalux Awarded $2.3 Million Research Grant
businesswire.com (Nov 5 2007)
Funding
CLEVELAND--(BUSINESS WIRE)--Imalux Corporation (“Imalux”), a medical device company and developer of the Niris™ Imaging System based on Optical Coherence Tomography (“OCT”) technology, today announced the receipt of a Fast-Track research grant from the National Cancer Institute of the National Institutes of Health. The award of up to $2.3 million is to fund Imalux’s accelerated development of video rate Optical Coherence Tomography for early stage cancer visualization. The Phase 1 funding ...
Pioneering Cancer treatment technology backed by London Seed Capital
BBAA - Home (Oct 27 2007)
Funding
Optical imaging company Michelson Diagnostics has secured £600,000 of early stage funding, enabling it to further enhance its pioneering technology and pursue in-vivo trials in a clinical environment. This innovative, next generation, imaging technology addresses the key need for clinicians to see, during an operation and in real time, the location and extent of a tumour, for a range of cancer types. This enables faster, more accurate cancer surgery, with ...
Imalux Closes Series C Funding Round
dBusinessNews (Sep 28 2007)
Funding
dBusinessNews.com - CLEVELAND -- Imalux Corporation (“Imalux”), a medical device company and developer of the Niris™ Imaging System based on Optical Coherence Tomography (“OCT”) technology, today announced the successful closing of its Series C Preferred ...
Imalux Closes $5.1M Series C Funding Round
Find Articles at BNET.com (Sep 28 2007)
Funding
Wireless News 09-28-2007 Imalux Closes Series C Funding Round WIRELESS NEWS-September 28, 2007-Imalux Closes Series C Funding Round (C)2007 10Meters - http://www.10meters.com Imalux Corp., a medical device company and developer of the Niris Imaging System based on Optical Coherence Tomography (OCT) technology, announced the successful closing of its Series C Preferred Shares Offering. Proceeds from the Offering were $5.1 million, including conversion of $2.5 million of bridge financing. Lead investors ...
Lantis Laser Successfully Completes $2.5 Million Financing
DENVILLE, N.J., May 8, 2007 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), a New Jersey based development stage company, is pleased to announce that it has recently completed a private placement for $2.5 million. This round of financing enables Lantis to complete Phase 2 development of its OCT (Optical Coherence Tomography) Dental Imaging System(tm) designed for the early detection of oral diseases such as caries (decay) and periodontal ...
DENVILLE, N.J., May 8, 2007 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), a New Jersey based development stage company, is pleased to announce that it has recently completed a private placement for $2.5 million. This round of financing enables Lantis to complete Phase 2 development of its OCT (Optical Coherence Tomography) Dental Imaging System(tm) designed for the early detection of oral diseases such as caries (decay) and periodontal ...
Lantis Laser (LLSR) Successfully Completes $2.5 Million Financing
DENVILLE, NJ (May 8, 2007) Lantis Laser Inc., (PINKSHEETS:LLSR) a New Jersey based development stage company, is pleased to announce that it has recently completed a private placement for $2.5 million.
DENVILLE, NJ (May 8, 2007) Lantis Laser Inc., (PINKSHEETS:LLSR) a New Jersey based development stage company, is pleased to announce that it has recently completed a private placement for $2.5 million.
Optovue, an ocular disease treatment co., raises $10.5M
VentureBeat (Mar 30 2007)
Ophthalmology,
Funding
Optovue, a Fremont, Ca. maker of devices that improve diagnosis and treatment of ocular disease, has received $10.5 million in second round of funding, the company announced said. Based on high speed and high resolution Fourier-Domain OCT technology, the products help with retina conditions such as macular degeneration, diabetic retinopathy, glaucoma, and other macular diseases. Trevi Health Ventures led the round, which also included Acorn Campus Ventures, HNQ Asia Pacific, ...
Optovue raises $10.5M
bizjournals (Mar 30 2007)
Ophthalmology,
Funding
Ophthalmic device maker Optovue Corp. said Friday it received $10.5 million in second-round funding. Fremont-based Optovue said New York-based Trevi Health Ventures led the investment, followed by several partners from Optovue's previous funding round. The company said the money will be used to expand production of the its RTVue device, which was recently released outside the United States, as well as advance development of the company's
Bioptigen Receives FDA Clearance and Two Phase II SBIR Awards; Company to Exhibit at Major Technology Conference
bioptigen.com (Jan 17 2007)
Funding
Bioptigen completes series A funding round, investment closes at $1.3 million
newsrx.com (Sep 13 2006)
Funding
Bioptigen, an optical technology company developing proprietary advances in the field of optical coherence tomography (OCT), announces the closing of its Series A round of funding. The round closed at $1.3 million and investors included the Piedmont Angel Network, the Inception Micro-Angel Fund and qualified individuals. Bioptigen will be The Piedmont Angel Network's PAN Two Fund's first investment. "We are exhilarated to have completed our first funding round with the ...
Bioptigen Completes Series A Round Funding
bioptigen.com (Aug 7 2006)
Funding
FOR IMMEDIATE RELEASE August 7, 2006 Contact: Winn Maddrey 704.905.2912 BIOPTIGEN COMPLETES SERIES A FUNDING ROUND Investment Closes at $1.3 Million DURHAM, N.C. – Bioptigen, an optical technology company developing proprietary advances in the field of optical coherence tomography (OCT), announces the closing of its Series A round of funding. The round closed at $1.3 million and investors included the Piedmont Angel Network, the Inception Micro-Angel Fund and qualified individuals. ...